Abstract: A building may include a floor, a dome having a vent, and an internal ceiling that divides areas underneath the dome into first and second chambers. The internal ceiling may have an aperture that is structured to allow air to pass from the first chamber into the second chamber. The building may also include an air inlet configured to allow air to travel from outside the building into the first chamber and an air moving device that is configured to facilitate the movement of the air. The building may also include an air cooling element that is configured to cool the air as it travels from outside the building into the first chamber.

Abstract: A method or system for imaging and quantifying placental blood perfusion using magnetic resonance image. The method or system provides a noninvasive means of assessing placental function and oxygenation from T2* images without the administration of an exogenous contrast agent. The method or system provides quantitative information regarding the number and spatial distribution of perfusion domains which subdivide the placenta into functional units where oxygen transport occurs, along with estimates of fetal oxyhemoglobin concentration, descriptors of placental oxygen reserve, and parameters representing the facility with which oxygen transport from the maternal to fetal vasculature occurs.

Abstract: An example method includes generating, using a multi-scale block of a convolutional neural network (CNN), a first output image based on an optical coherence tomography (OCT) reflectance image of a retina and an OCT angiography (OCTA) image of the retina. The method further includes generating, using an encoder of the CNN, at least one second output image based on the first output image and generating, using a decoder of the CNN, a third output image based on the at least one second output image. An avascular map is generated based on the third output image. The avascular map indicates at least one avascular area of the retina depicted in the OCTA image.

Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

Abstract: A method of treating heart disease and/or injury in a subject includes administering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of PTP?.

Abstract: Disclosed herein are methods for simulating the results of a visual field (VF) test using an optical coherence tomography (OCT) system. The disclosed methods may utilize structural information extracted from OCT image datasets, such as thickness measurements, or may utilize functional information, such as blood perfusion measurements, extracted from OCT angiography (OCTA) image datasets.

Abstract: The present disclosure provides polypeptides that have the ability to repair DNA damage by recognizing and removing a wide variety of DNA damage and distortions in double-stranded DNA. In particular, the polypeptides have the ability to remove cyclobutane pyrimidine dimers (CPDs) and/or (6-4) photoproducts from DNA. The polypeptides include at least one heterologous targeting sequence.

Abstract: Disclosed are implantable ocular drainage devices that include a reversible switch mechanism to control flow through the drainage device. The devices include a drainage tube and a reversible, bi-stable switch mechanism that includes first and second stationary magnets spaced apart from one another and a magnetic or ferromagnetic mobile element moveably disposed in a channel in the housing.

Abstract: Disclosed herein are recombinant CMV vectors which may comprise a heterologous antigen that can repeatedly infect an organism while inducing a CD8+ T cell response to immunodominant epitopes of the heterologous antigen. The CMV vector may comprise a deleterious mutation in the US11 glycoprotein or a homolog thereof.

Abstract: Disclosed herein are methods and systems for automated detection of shadow artifacts in optical coherence tomography (OCT) and/or OCT angiography (OCTA). The shadow detection includes applying a machine-learning algorithm to the OCT dataset and the OCTA dataset to detect one or more shadow artifacts in the sample. The machine-learning algorithm is trained with first training data from first training samples that include manufactured shadows and no perfusion defects and second training data from second training samples that include perfusion defects and no manufactured shadows. The shadow artifacts in the OCTA dataset and/or OCT dataset may be suppressed to generate a shadow-suppressed OCTA dataset and/or a shadow-suppressed OCT dataset, respectively. Other embodiments may be described and claimed.

Abstract: Disclosed herein are methods of high-throughput mapping of viral neutralizing antibody epitopes. Also disclosed are in vitro immunoprecipitation-based adenoassociated virus Barcode-Seq-based methods of mapping viral neutralizing antibody epitopes. In some embodiments, a method of high-throughput mapping of viral NtAb conformational epitopes can be utilized, which may comprise HP scanning of mutant viral libraries, immunoprecipitation (IP), and/or next-generation sequencing (NGS) technology. In some embodiments, a method of identifying one or more dominant epitopes in a viral vector may comprise contacting a mutant capsid of a virus with serum from a subject previously exposed to the virus and immunopredpitating serum immunoglobulins from the serum. In various embodiments, the viral vector may be an AAV vector.

Abstract: Provided herein are optimized recombinant influenza HA polypeptides that elicit immune responses. Also provided are compositions and kits comprising the optimized HA polypeptides as well as methods of making and using the optimized HA polypeptides.

Abstract: An example method includes identifying training data indicating features of a sample population and clinical outcomes of the sample population. The clinical outcomes are associated with a heterogeneous condition. The method further includes generating decision trees in a Random Forest (RF) based on the training data, each one of the decision trees being configured to divide the sample population into multiple categories based on the features of the sample population. In response to generating the decision trees, a proximity matrix comprising multiple entries is generated using the RF. One of the entries indicates a proportion of the decision trees that categorize a first individual among the sample population and a second individual among the sample population into the same categories among the multiple categories. The method further includes identifying subgroups of the heterogeneous condition by detecting communities of the proximity matrix.

Abstract: Retreating stop ultrasound needle guide systems are disclosed. In one example approach, a needle guide system includes a guiding component which can be positioned at different locations and angles on a mounting component, where the mounting component can be coupled to a distal end of an ultrasound probe. When positioned at the different locations and angles on the mounting component, the guiding component can guide a needle through the skin of a patient at a constant point and when the needle is advanced so that a hub of the needle reaches a stop of the guiding component, a tip of the needle is positioned directly underneath the ultrasound at a pre-selected depth.

Abstract: Disclosed are recombinant CD74 polypeptides mutated relative to the naturally occurring CD74 polypeptides with improved properties such as binding of CD74 ligands such as MIF and RTL1000 as well as polynucleotides that encode the polypeptides, expression vectors comprising the polynucleotides, bacteria that include the expression vectors, and methods of making the recombinant polypeptides.

Abstract: Disclosed herein are recombinant CMV vectors comprising heterologous antigens and microRNA recognition elements to silence expression of CMV genes in the presence of microRNA derived from myeloid cells, an active UL128 protein and an active UL130 protein. Also disclosed are recombinant CMV vectors comprising heterologous antigens and microRNA recognition elements to silence expression of CMV genes in the presence of microRNA derived from myeloid cells, an inactive UL128 protein and an inactive UL130 protein. Also disclosed are methods of generating an unconventional immune response using these vectors. Such an immune response is characterized by generation of a CD8+ T cell response that is predominantly restricted by MHC-II.

Abstract: Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.

Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

Abstract: Methods and systems for suppressing shadowgraphic flow projection artifacts in OCT angiography images of a sample are disclosed. In one example approach, normalized OCT angiography data is analyzed at the level of individual A-scans to classify signals as either flow or projection artifact. This classification information is then used to suppress projection artifacts in the three dimensional OCT angiography dataset.

Abstract: Compositions and methods are provided for modulating adeno-associated virus (AAV) infection. For example, compositions and methods are provided for enhancing permissiveness of a target cell to AAV infection (e.g., by increasing levels of AAVR (KIAA0319L) in the cell), for reducing permissiveness of a target cell to AAV infection (e.g., by reducing levels of AAVR in the cell), and for nucleic acid delivery (e.g., by (i) increasing permissiveness of a target cell to AAV infection, e.g., by increasing the amount of AAVR in the cell; and (ii) contacting the target cell with an AAV particle that includes a nucleic acid of interest). Also provided are screening methods and kits for practicing the methods of the disclosure.